Patients that have Undergone Hemodialysis Exhibit Lower Amyloid Deposition in the Brain: Evidence Supporting a Therapeutic Strategy for Alzheimer’s Disease by Removal of Blood Amyloid
Affiliations: [a] Faculty of Clinical Engineering, School of Health Sciences, Fujita Health University, Toyoake, Japan | [b] Department of Anatomy I, School of Medicine, Fujita Health University, Toyoake, Japan | [c] Department of Diagnostic Pathology, School of Medicine, Fujita Health University, Toyoake, Japan | [d] Department of Nephrology, School of Medicine, Fujita Health University, Toyoake, Japan | [e] Faculty of Medical Technology, School of Health Sciences, Fujita Health University, Toyoake, Japan
Correspondence:
[*]
Correspondence to: Nobuya Kitaguchi, PhD, Faculty of Clinical Engineering, School of Health Sciences, Fujita Health University, 1-98, Dengakugakubo, Kutsukake-cho, Toyoake 470-1192 Japan. Tel.: +81 562 93 2657; Fax: +81 562 93 4595; E-mail: nkitaguc@fujita-hu.ac.jp.
Note: [1] Present address: Department of Anatomy, Gifu University Graduate School of Medicine.
Abstract: As a proof of concept that removal of blood amyloid-β (Aβ) can reduce Aβ deposition in the brains of patients with Alzheimer’s disease, cortices of patients who had undergone hemodialysis (HD), which removes Aβ from the blood, were histochemically analyzed; postmortem brain sections were stained with anti-Aβ antibodies. Brains from patients who had undergone HD had significantly fewer senile plaques than those of patient who had not undergone HD. This significant difference was also confirmed by silver staining. Our findings suggest that removal of blood Aβ by hemodialysis results in lower accumulation of Aβ in the brain.
